🇺🇸 PegIFN alfa-2a in United States

4 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 4

Most-reported reactions

1. Hepatic Encephalopathy — 1 report (25%)
2. Hyperglycaemia — 1 report (25%)
3. Jaundice — 1 report (25%)
4. Pancytopenia — 1 report (25%)

Source database →

Frequently asked questions

Is PegIFN alfa-2a approved in United States?

PegIFN alfa-2a does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for PegIFN alfa-2a in United States?

The Second Affiliated Hospital of Chongqing Medical University is the originator. The local marketing authorisation holder may differ — check the official source linked above.